Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per Week

Not Applicable

Active, not recruiting

• Conditions: Virally Suppressed People With HIV

• Registration Number: NCT06773754
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The goal of this clinical trial is to learn if fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) taken as 5 days per week (5/7, FOTO group) works well as continuous therapy as 7 days per week (7/7, Daily group) in HIV-1-Infected participants who are virally suppressed. The main questions it aims to answer are:

1. Do the lowest concentrations of BIC at baseline, Week 4, 28, and 52 in the FOTO group achieve the adequate BIC level to control HIV infection?

2. Do the HIV viral loads at Week 4, 28, and 52 remain suppressed in the FOTO group? Researchers will compare FOTO group to Daily group to see if FOTO group can achieve the adequate BIC levels and HIV viral suppression.

Participants will:

1. Take fixed-dose BIC/FTC/TAF 5 days a week or everyday Blood sampling for the lowest concentrations of BIC at baseline, Week 4, 28, and 52

2. Blood sampling for HIV viral loads every 3 months for one year after the enrollment

3. Keep a diary of their drug compliance.

4. Be invited to change to take fixed-dose BIC/FTC/TAF 5 days a week after Week 52 if they are randomised to Daily group initially.

5. Be followed for 2 years after the enrollment.

Detailed Description

This protocol describes an open-label, single-center study to evaluate the safety and efficacy of 5/7 intermittent therapy versus 7/7 continuous therapy of coformulated BIC/FTC/TAF FDC in PLWH who are virologically suppressed. The study is comprised of two periods as shown in Figure 1. The first period is an observational 2-week run-in period during which participants who meet the screening criteria will receive daily oral dose of BIC/FTC/TAF. The second study period is a 48-week treatment period (defined as the time the first dose of study drug is administered on Day 1 after randomization through completion of Week 48 assessments) which will evaluate the PK, efficacy, and safety of 5 consecutive days on treatment (typically Monday through Friday) followed by 2 days off treatment (five-on, two-off or 5/7 treatment schedule) regimen compared to continuous therapy (or 7/7) regimen in virologically suppressed HIV-1-infected patients. The study will include Screening of up to 30 days to determine eligibility of participants and to complete disease-related assessments. A self-reported adherence diary will be given to all participants to record whether they take ART during the study period. If the participants in the 5/7 regimen group miss doses during the 5-on days, the missed doses could be taken during the 2-off days to complete the 5 doses a week. Participants will provide written informed consent and visit the study site to complete the screening assessment during the screening period. If the participants are women, contraception is required during study period.

Following successful screening, the 2-week run-in period will commence, during which participants will receive daily coformulated BIC/FTC/TAF dose and only participants with 100% compliance will be eligible to be enrolled in 52-week treatment period. Upon confirmation of eligibility, participants will be randomized in a 1:1 ratio to received 5 days on and 2 days off regimen (5/7 regimen) or continuous therapy (7/7 regimen). Approximately 60 subjects are planned to be randomized. Participants excluded before randomization will be replaced at Screening. After randomization (baseline +/- 1 week), participants will return to the study site at week 4 (+/- 2 weeks) and subsequently every 12 weeks (+/- 3 months) until Week 52 (+/- 1 month) (Table 1). To assess the drug compliance of the study subjects, it is required for them to fill in the paper or online electronic diary cards. Pharmacological study (PK), efficacy and safety assessment will be conducted at Weeks 4, 28 and 52; and QoL will be assessed at baseline and 52 by the electronic form of SF-36v2. The primary endpoint will be assessed at Weeks 4, 28 and 52. Once subjects completed 52-week treatment period, subjects will return to the study site for safety follow-up visit 30 days +/- 3 days after the last dose. If PLWH on 5/7 regimen had virological failure (\>1,000 copies/mL) at week 4, 28, or 52, they would be withdrawn from the study. Their HIV isolates would be sent for resistant testing. They would start daily regimen, and their PVL would be checked every 3 months until their PVL return to be suppressed (\<200 copies/mL). After Week 52, the participants in continuous therapy (or 7/7) regimen will be invited to change to 5 consecutive days on treatment (typically Monday through Friday) followed by 2 days off treatment (five-on, two-off or 5/7 treatment schedule) regimen. All participants will be followed for 2 years after the enrollment.

Study Timeline

• Study Start: 2022-06-14
• Primary Completion: 2023-09-01
• Status Verified: 2025-01
• Study First Submitted: 2025-01-08
• Study First Submitted QC: 2025-01-08
• Last Update Submitted: 2025-01-08
• Study First Posted: 2025-01-14
• Last Update Posted: 2025-01-14
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. PLWH aged 20 years or more
2. PLWH with virological suppression (<50 copies/mL) for 6 months or more
3. PLWH who have received coformulated BIC/FTC/TAF for at least 2 weeks or more

Exclusion Criteria

1. PLWH with a history of intolerance to antiretroviral regimens containing an integrase inhibitor, ETC/lamivudine, and tenofovir disoproxil fumarate/TAF
2. PLWH with a history of genotypic resistance to integrase inhibitors or TFV
3. PLWH with concurrent use of medications known to pharmacokinetically interact with BIC

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
BIC trough plasma concentrations	From enrollment to Week 4, 28, and 52 during treatment period	the proportion of study participants maintaining BIC trough plasma concentrations above the paEC95 of 162 ng/mL after 2 days off coformulated BIC/FTC/TAF at Week 4, 28, and 52 during treatment period

Secondary Outcome Measures

Name	Time	Method
HIV viral suppression	From the enrollment to Week 4, 28, 52, 96 during treatment period	the proportions of participants with PVL \<50 copies/mL at Week 4, 28, and 52 during treatment period and quality of life (QoL) at baseline and Week 52

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei City, Taiwan